TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06299904

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Air-pulse Stimulation
Description: Connected the oxygen humidification bottle to a fibreoptic endoscope, then inserted the terminal into the nasal cavity and the pulse sensation stimulation generated by oxygen was transmitted through the internal port of the fibreoptic endoscope to the anterior wall of the pyriform recess or to the folds of the arytenoepiglottis. (5 min once a day for 2 weeks)

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Conventional air-pulse stimulation
Description: The terminal airway of the air pulse was placed in the oral cavity, specifically in the patient's palatoglossal arch, pharyngeal posterior wall, tongue base, and other areas. The airbag was quickly squeezed to generate airflow and stimulate the mucosa.(5 min once a day for 2 weeks)
Study: NCT05203549

Intervention type: PROCEDURE
Intervention: Tumor biopsy
Description: Patients with gastric cancer will undergo tumor biopsy before receiving neoadjuvant therapy, conversion therapy, or palliative therapy
Study: NCT02815124

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Post Cochlear Implant surgery, subject will receive activation/programming of their implant using Standard of Care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Image-Guided Cochlear Implant Programming
Description: Post Cochlear Implant surgery, subject will receive activation/programming of their implant using Image-Guided Cochlear Implant Programming
Study: NCT05289375

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A sample will be taken from all participants in group P following the manufacturer's instructions for the design of the autovaccine, using a sterile swab that will be placed in a transport medium and sent to the laboratory (as in group T). After 1 month from the collection of the sample, the laboratory will send it in a container/dispenser (with the same appearance in both groups). The content in group P will receive a placebo in the same dosage and temporality as group T, it will be the same except for the active ingredient, that is, only thimerosal, methylcellulose, sodium chloride and orange essence.
Study: NCT05999513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: casdatifan
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: casdatifan
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: casdatifan
Description: Administered as specified in the treatment arm
Study: NCT05431946

Intervention type: BEHAVIORAL
Intervention: Advance Care Planning and the consequent actions
Description: The palliative care intervention is based on the advance care planning process and the actions taken as a consequence of these conversations. The goal is the identification, assessment, and treatment of physical, psychosocial, or spiritual symptoms and problems.~Advance care actions~These are the actions taken to fulfill the advance care plan and can include, but are not limited to:~treatments: pharmacological, psychosocial (priest, psychologist, etc.) referrals: rehabilitation, specialized palliative care team, hospice, etc. communication initiatives with relatives, primary care, public authorities
Study: NCT05913635

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Consumption of lunch and dinner, with no breakfast
Description: The day before intervention day, all participants will be provided with 3 nutritionally balanced meals which are designed by the investigators. On the no-breakfast intervention day, participants are instructed to fast and only be allowed to consume water until 1.00 p.m. and consume the above-designed lunch and dinner at 1.00 p.m. and 8.00 p.m. Additionally, all participants are informed that they are only allowed to consume water between meals and before receiving breakfast at 7.30 a.m. the following day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Consumption of breakfast and lunch, with no dinner
Description: The day before intervention day, all participants will be provided with 3 nutritionally balanced meals which are designed by the investigators. On the no-dinner intervention day, participants are instructed to consume the above-designed breakfast and lunch at 7.30 a.m. and 1.00 p.m., and no dinner. Additionally, all participants are informed that they are only allowed to consume water between meals and before receiving breakfast at 7.30 a.m. on the following day.
Study: NCT06158568

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Percutaneous Electrical Nerve Stimulation
Description: Application of a electrical current percutaneously (at the motor response intensity) targeting the suprascapular and axillar nerves

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Percutaneous Electrical Nerve Stimulation
Description: Application of sham electrical current (no intensity) percutaneously targeting the suprascapular and axillar nerves

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Application of three weeks of progressive exercises targeting the shoulder musculature

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Application of three weeks of progressive exercises targeting the shoulder musculature

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Exercise
Description: Application of three weeks of progressive exercises targeting the shoulder musculature
Study: NCT06559189

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19x22 CAR T
Description: The CD19 CAR contains an FMC63 binding domain, a CD28 hinge/transmembrane/endodomain, and a CD3 zeta endodomain. The CD22 CAR contains the binding domain (m971), a CD8alpha hinge and transmembrane domain, a 41BB endodomain, and a CD3 zeta endodomain.
Study: NCT05622045

Intervention type: BEHAVIORAL
Intervention: Voice data
Description: Recorded response to a question about their participation in a weight loss study.
Study: NCT06430502

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor Treatment Vaccine; PD-1/L1 inhibitors
Description: Before and after the patient's treatment period using PD-1 inhibitors，patients will receive tumor treatment vaccine(TTV), which would be given deep subcutaneously in the arm or near the tumor.The initial dose is 1ml each time, if the reaction isn't obvious, the dose can be appropriately increased to 2.5-4.0ml each time.The interval between injections can be shortened or extended depending on the patient's condition and response.
Study: NCT06118814

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Body Awareness Therapy Exercise
Description: Body awareness therapy exercises were applied to the subjects in this group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Exercise
Description: Virtual reality exercises were applied to the subjects in this group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core Stability Exercise
Description: Core stabilization exercises were applied to the subjects in this group.
Study: NCT06117748

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pressure controlled ventilation-volume guaranteed
Description: Respiratory parameters will be set as: actual tidal volume 8 mL/kg actual body weight, respiratory rate 12 breaths/min, PEEP of five mmHg, oxygen flow 1 L/min, fraction inspired oxygen (FiO2) 0.6, and I:E ratio of 1:2.~Respiratory parameters will be kept constant if ETCO2 is \<45 mmHg. When ETCO2 exceed 45 mmHg, respiratory rate or tidal volume will be adjusted to maintain ETCO2 below 45 mmHg.

Intervention type: OTHER
Group type: OTHER
Intervention: Volume controlled ventilation
Description: Respiratory parameters will be set as: actual tidal volume 8 mL/kg actual body weight, respiratory rate 12 breaths/min, PEEP of five mmHg, oxygen flow 1 L/min, fraction inspired oxygen (FiO2) 0.6, and I:E ratio of 1:2.~Respiratory parameters will be kept constant if ETCO2 is \<45 mmHg. When ETCO2 exceed 45 mmHg, respiratory rate or tidal volume will be adjusted to maintain ETCO2 below 45 mmHg.
Study: NCT05270317

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Graft Cultivation and Harvesting
Description: Participants will be randomly assigned preoperatively into three surgical groups depending on cultivation time: early-stage group, medium-stage group and late-stage group . Bone Graft Cultivation is a two-stage procedure aiming at generating new bone tissue for grafting by periosteal elevation . The first stage is the insertion of space-occupying implant which is responsible for keeping periosteal elevation for a defined time to stimulate new bone formation. The second stage is the extraction of woven bone that has been formed together with the implant.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Graft Cultivation and Harvesting
Description: Participants will be randomly assigned preoperatively into three surgical groups depending on cultivation time: early-stage group, medium-stage group and late-stage group . Bone Graft Cultivation is a two-stage procedure aiming at generating new bone tissue for grafting by periosteal elevation . The first stage is the insertion of space-occupying implant which is responsible for keeping periosteal elevation for a defined time to stimulate new bone formation. The second stage is the extraction of woven bone that has been formed together with the implant.
Study: NCT05325658

Intervention type: OTHER
Intervention: FEES, treatment with modified diet, electrical swallowing muscle stimulation.
Description: Endoscopic swallowing assessment (FEES) consists of three parts:1) assessment of mouth, throat anatomy and more; 2) the patient is given to swallow a certain amount and consistency of liquids and solid food. 3) evaluated: preparation of the bolus for swallowing, aspiration. An 8-point Penetration-Aspiration scale is described.Swallowing exercises. Swallowing exercises are also used in practice, which can help coordinate the swallowing muscles or stimulate the nerves involved in the swallowing reflex.Transcutaneous electrical stimulation is a method of treating dysphagia in which weak electrical impulses stimulate the muscles in the neck area associated with swallowing. In patients with oropharyngeal dysphagia, patients have great difficulty swallowing water of normal consistency or other non-thick liquids, so they should be thickened with special thickeners to such an extent that the patient does not experience discomfort and be able to swallow.
Study: NCT05600036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESK-001
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESK-001
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESK-001
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESK-001
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESK-001
Description: Oral tablet
Study: NCT05270317

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Graft Cultivation and Harvesting
Description: Participants will be randomly assigned preoperatively into three surgical groups depending on cultivation time: early-stage group, medium-stage group and late-stage group . Bone Graft Cultivation is a two-stage procedure aiming at generating new bone tissue for grafting by periosteal elevation . The first stage is the insertion of space-occupying implant which is responsible for keeping periosteal elevation for a defined time to stimulate new bone formation. The second stage is the extraction of woven bone that has been formed together with the implant.
Study: NCT04611113

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Immunonutrition
Description: In addition to nutritional counseling, patients will receive two servings of an oral high-calorie-high-protein nutritional liquid supplement enriched in immunonutrients (Impact®). The intervention will start 10-15 days before anticancer treatment initiation and will continue until treatment termination or dropout.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control Nutritional Support
Description: In addition to nutritional counseling, patients will receive two servings of an oral high-calorie-high-protein nutritional liquid supplement. The intervention will start 10-15 days before anticancer treatment initiation and will continue until treatment termination or dropout.
Study: NCT06118814

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Exercise
Description: Subjects in this group implemented a home exercise program.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Exercise
Description: Subjects in this group implemented a home exercise program.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home Exercise
Description: Subjects in this group implemented a home exercise program.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Exercise
Description: Subjects in this group implemented a home exercise program.
Study: NCT05600036

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablet
Study: NCT05199909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zanubrutinib
Description: The initial dose is 80mg/day. If the treatment is ineffective after 4 weeks, and under the condition of good safety, the researcher will judge that the dosage should be added to 80mg twice/day，or a higher dose for oral maintenance. The maximum dose is 160mg twice a day. The duration of zanubrutinib is 24 weeks.~In case of intolerable adverse reactions, such as severe infection, severe bleeding, hematopenia, arrhythmia, etc., investigator can reduce the dose of zanubrutinib, or withdraw from clinical trials as appropriate.
Study: NCT06276127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Bisoprolol
Description: Participants in this group will receive a single oral dose of Bisoprolol, set at a dosage of 5 mg, with a maximum dose limit of 5 mg.

Intervention type: DRUG
Group type: OTHER
Intervention: Intravenous Diltiazem
Description: Participants in this group will be administered a single intravenous dose of diltiazem at a dosage of 0.25 mg/kg, with a maximum dose capped at 30 mg.
Study: NCT06420674

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unified Protocol for Transdiagnostic Treatment of Emotional Disorders
Description: The Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders is a psychological intervention that focuses on a wide range of emotional disorders (i.e., anxiety, depression and related disorders). It allows care for comorbid disorders, subclinical or unspecified symptoms reducing associated costs and improving response to treatment.~In our study, the Unified Protocol preventive program will be applied throughout 10 online modules. Women will have access to a web-page (moodle version) that includes audiovisual materials (e.g., written manual, videos, editable registers) and psychological assessments.
Study: NCT05439577

Intervention type: DRUG
Intervention: Mucopolysaccharide Polysulfate Cream
Description: Patients using Hirudoid® alone

Intervention type: DRUG
Intervention: Mucopolysaccharide Polysulfate Cream and glucocorticoids
Description: Patients using Hirudoid® and glucocorticoids (Combination therapy, but not always)
Study: NCT04519541

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-Invasive Thermal Ablation of the Medial Branch Nerves using the Neurolyser XR
Description: Thermal ablation of the medial nerve branch using High Intensity Focused Ultrasound
Study: NCT05709444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bremelanotide
Description: Bremelanotide is a cyclic, heptapeptide analog of the endogenous peptide alpha melanocortin stimulating hormone (αMSH).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAAS inhibition therapy
Description: RAS-acting agents are medicines acting on a hormone system that helps to control blood pressure and the amount of fluid in the body.
Study: NCT06000501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serdexmethylphenidate/dexmethylphenidate
Description: Azstarys capsules for once-daily oral use for three weeks. Flexible dose starting at 39.2 mg serd-mph/7.8 mg d-mph and moving up to 52.3 mg serd-mph/10.4 mg d-mph.
Study: NCT06649058

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systemic Therapy
Description: Participants will receive systemic therapy as a standard of care therapeutic option

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systemic Therapy
Description: Participants will receive systemic therapy as a standard of care therapeutic option

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systemic Therapy
Description: Participants will receive systemic therapy as a standard of care therapeutic option

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systemic Therapy
Description: Participants will receive systemic therapy as a standard of care therapeutic option

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systemic Therapy
Description: Participants will receive systemic therapy as a standard of care therapeutic option

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Participants will receive systemic therapy as a standard of care therapeutic option

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Participants will receive systemic therapy as a standard of care therapeutic option

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Participants will receive systemic therapy as a standard of care therapeutic option

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Participants will receive systemic therapy as a standard of care therapeutic option

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Participants will receive systemic therapy as a standard of care therapeutic option
Study: NCT05148403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glibenclamide
Description: Glibenclamide was given orally or by nasal feeding
Study: NCT06463483

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic 780G System
Description: Automated insulin delivery using Medtronic 780G system

Intervention type: DEVICE
Group type: OTHER
Intervention: Continuous Glucose Monitoring
Description: Usual care with continuous glucose monitoring
Study: NCT06605430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medical Cannabis
Description: The Early Cannabis group will be provided with 8 weeks of medical cannabis at no charge. Following 8 weeks of cannabis, the Early Cannabis group will be observed as per standard of care for the remaining 8 weeks. The Delayed Cannabis group will receive usual care for the first 8 weeks, and then be provided up to 8 weeks of medical cannabis at no charge for the second 8 weeks. Prior to receiving cannabis, patients must first be certified by a provider for eligibility to receive medical cannabis before registering with the Minnesota Medical Cannabis Program. Collective experience with precise dosage CBMs supports a pharmacist-guided titration protocol with robust patient input and close patient follow up. The treating pharmacist in the Minnesota Medical Cannabis Program thoroughly instructs patients on dose titration at the initial visit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medical Cannabis
Description: The Early Cannabis group will be provided with 8 weeks of medical cannabis at no charge. Following 8 weeks of cannabis, the Early Cannabis group will be observed as per standard of care for the remaining 8 weeks. The Delayed Cannabis group will receive usual care for the first 8 weeks, and then be provided up to 8 weeks of medical cannabis at no charge for the second 8 weeks. Prior to receiving cannabis, patients must first be certified by a provider for eligibility to receive medical cannabis before registering with the Minnesota Medical Cannabis Program. Collective experience with precise dosage CBMs supports a pharmacist-guided titration protocol with robust patient input and close patient follow up. The treating pharmacist in the Minnesota Medical Cannabis Program thoroughly instructs patients on dose titration at the initial visit.
Study: NCT06603961

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPG-EB group
Description: Customized-pressure guided elastic bandage group
Study: NCT05136313

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time-restricted eating
Description: 16 weeks of TRE consisting of an 8-hour eating window.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time-restricted eating
Description: 16 weeks of TRE consisting of an 8-hour eating window.
Study: NCT06615713

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Steerable Ureteroscopic Renal Evacuation (SURE) with CVAC System
Description: The CVAC Aspiration System is a sterile, single use, steerable ureteral catheter system with integrated vision, irrigation and aspiration for the treatment and removal of urinary stones (kidney stones, fragments, and dust).
Study: NCT06488560

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: commercial blenderized tube feed (CBTF)
Description: Based on assessment by a dietician the participant will be fed the commercial blenderized formula to meet their caloric needs

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: commercial formulas (CF)
Description: Participant will be fed the commercial formula to meet their caloric needs per standard of care
Study: NCT04980716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multiple cardiovascular drugs related to Golden Triangle
Description: Based on impedance cardiography results at each timepoints, cardiovascular drug treatment and exercise plan will be given in the intervention group.
Study: NCT06618443

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scapular mobilization with movement
Description: The treatment consisted of scapular mobilization with arm movement in all directions for 15 min/session for 3 sessions/week for 4 weeks. Scapular mobilization included scapular upward glide and downward glid. Scapular upward glide was performed with shoulder adduction and extension, while scapular downward glide was performed with shoulder abduction and flexion.